Ara
Toplam kayıt 14, listelenen: 11-14
Generic Imatinib Mesylate Is As Effective As Original Glivec In The Clinical Management Of Cml
(Akad Doktorlar Yayınevi, 2015)
Unsustainable drug prices in chronic myeloid leukemia (CML) and cancer may be causing harm to patients. The aim of this multi-center study is to assess the efficacy of generic imatinib mesylate (IM) over Glivec in terms ...
Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in Cml
(Akad Doktorlar Yayınevi, 2012)
Dasatinib is considered an effective treatment agent in imatinib-resistant and newly diagnosed chronic phase CML patients. Patients receiving dasatinib 100 mg once daily regime suffered significantly fewer thrombocytopenia ...
Retrospective Evaluation of Patients Treated with Dasatinib For Philadelphia Positive Leukemias: Turkish Experience of 16 Months
(Akad Doktorlar Yayınevi, 2009)
This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94 +/- 4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. ...
Renin-Angiotensin System (Ras) Expressions in Myeloid Leukemic Cell Lines
(Akad Doktorlar Yayınevi, 2013)
The aim of this study is to search critical renin-angiotensin system (RAS) elements in myeloid leukemic cell lines. Human acute myeloid leukemia (AML) cell lines, KG-1 and HL-60, were cultured. We searched for the gene ...